Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

Batgi H., Dal M. S., ERKURT M. A., KUKU İ., Kurtoglu E., Hindilerden I. Y., ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.60, sa.5, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.transci.2021.103242
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: Extracorporeal photopheresis, Allogeneic stem cell transplantation, Acute graft versus host disease, RETROSPECTIVE ANALYSIS, PHOTOCHEMOTHERAPY, THERAPY, GVHD, ECP
  • İnönü Üniversitesi Adresli: Evet

Özet

Background and objectives: Extracorporeal photopheresis (ECP) is one of the second-line treatment strategies in steroid-refractory acute graft-versus-host disease (aGvHD). We aimed to share our multicenter experience using ECP in our steroid-refractory aGvHD patients. Materials and methods: A retrospective observational series of 75 aGvHD patients from 4 transplant centers were analyzed. All ECP procedures were performed with the off-line system. All patients received ECP as second-line therapy. Results: 74.7 % of aGvHD patients were grade 3 or 4. The overall response rate was 42.7 % (32/75) in aGvHD including 17 complete responses (22.7 %). Median follow-up was 6 months (range, 1-68). Median overall survival (OS) was 5 months for non-responders and 68 months for responders (p < 0.001). Twenty-seven (36 %) patients are alive, and 48 (64 %) patients have died. Conclusions: Early initiated ECP could be an effective treatment alternative in patients with steroid-refractory aGvHD.